Addressing Dysautonomia: A Clinical Approach using Peptide Therapy, 2023, Kale Patel

Abstract
Autonomic dysfunction presents with a wide variety of disabling symptoms. Recently, the emergence of long-COVID has caused an exponential increase in patients with dysautonomia.

In patients whose autonomic dysfunction was perpetuated by a stroke, researchers discovered the administration of erythropoietin significantly reduced neuroinflammation. We attempted to apply these findings to our study by using EPO to address autonomic dysregulation. However, long-term erythropoietin administration is not sustainable due to the significant increase in hematocrit and increased blood vessel thickness that accompanies the increased production of red blood cells.

We discovered that regeneration of autonomic nerve fibres and immune modulation are key mechanisms for reversing autonomic dysfunction. Therefore, we sequenced a nonhematopoietic form of erythropoietin and linked the peptide chain to another polypeptide sequence genetically engineered from a calf thymus.

Subjects with long-COVID and CFS/ME receiving the peptide experienced a significant reduction in their autonomic symptoms as well as a significant increase in their autonomic nerve and small fibre nerve densities. In many cases, autonomic dysfunction was entirely reversed.
LINK

 

Kale Patel is the CEO of NeuroSY, seems to be something based at Stanford University. His LinkedIn says that they research treatments for LC and ME/CFS using nabobots (microscopic robots), AI, and peptides. He states that they are funded by 5 AM Ventures. So we might see more from them in the future.

 

The paper states that treatments for ME/CFS may include CBT and GET, so it doesn’t seem like he has a very good understanding of the field..

 

I just saw Seven of Nine do similarly in an old episode of Star Trek: Voyager.

 

I skimmed through the paper but I don't see any mention of GET and CBT. Can you point it out?

 

It's in the Introduction:

"The impact of CFS/ME on patients can be profound, with many individuals experiencing a significant decrease in their quality of life and ability to perform daily activities. In severe cases, patients may be bedridden or housebound, unable to work or engage in social activities, and may require significant support from family members or caregivers. Treatment approaches are typically focused on managing symptoms and improving quality of life, and may include medications to address pain or sleep disturbances, cognitive behavioral therapy, and graded exercise therapy. However, these treatments are not effective for all patients, and some individuals may require more individualized or intensive care to manage their symptoms."​

 

Right side of page 1, in line with the heading for the introduction.